Literature DB >> 15663750

Extended DR3-D6S273-HLA-B haplotypes are associated with increased susceptibility to type 1 diabetes in US Caucasians.

A M Valdes1, B Wapelhorst, P Concannon, H A Erlich, G Thomson, J A Noble.   

Abstract

Human leukocyte antigen (HLA)-DR3 haplotypes are associated with susceptibility to type 1 diabetes (T1D). Reports from Northern European populations show that an allele (D6S273*2) at a microsatellite mapping to HLA class III marks an extended DR3-B18 haplotype associated with increased susceptibility to T1D. Consistent with previous reports, D6S273*2 marked a highly predisposing DR3 haplotype in European origin, multiplex families from the USA. Furthermore, we observed on DR3 haplotypes that other D6S273 alleles were also significantly associated with both increased transmission (D6S273*5; P < 0.02) and decreased transmission (D6S273*7; P < 0.05) to affected individuals. The differential transmission was most evident among DR3-B8 haplotypes. Neither HLA-B*1801 nor any alleles of D6S273 were associated with increased T1D predisposition on DR4 haplotypes. These data indicate that multiple alleles of D6S273 mark a susceptibility locus whose effect we were able to detect only among DR3 haplotypes but not limited to DR3-B18 haplotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15663750     DOI: 10.1111/j.1399-0039.2005.00348.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  8 in total

1.  Several loci in the HLA class III region are associated with T1D risk after adjusting for DRB1-DQB1.

Authors:  A M Valdes; G Thomson
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

2.  The type 1 diabetes - HLA susceptibility interactome--identification of HLA genotype-specific disease genes for type 1 diabetes.

Authors:  Caroline Brorsson; Niclas Tue Hansen; Regine Bergholdt; Søren Brunak; Flemming Pociot
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

3.  In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Authors:  E Mbunwe; B J Van der Auwera; I Weets; P Van Crombrugge; L Crenier; M Coeckelberghs; N Seret; K Decochez; E Vandemeulebroucke; P Gillard; B Keymeulen; C van Schravendijk; J M Wenzlau; J C Hutton; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2013-05-28       Impact factor: 10.122

4.  HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families.

Authors:  Henry Erlich; Ana Maria Valdes; Janelle Noble; Joyce A Carlson; Mike Varney; Pat Concannon; Josyf C Mychaleckyj; John A Todd; Persia Bonella; Anna Lisa Fear; Eva Lavant; Anthony Louey; Priscilla Moonsamy
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

5.  Genetic variation within the HLA class III influences T1D susceptibility conferred by high-risk HLA haplotypes.

Authors:  A M Valdes; G Thomson; L F Barcellos
Journal:  Genes Immun       Date:  2010-01-07       Impact factor: 2.676

6.  Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.

Authors:  Sergey Nejentsev; Joanna M M Howson; Neil M Walker; Jeffrey Szeszko; Sarah F Field; Helen E Stevens; Pamela Reynolds; Matthew Hardy; Erna King; Jennifer Masters; John Hulme; Lisa M Maier; Deborah Smyth; Rebecca Bailey; Jason D Cooper; Gloria Ribas; R Duncan Campbell; David G Clayton; John A Todd
Journal:  Nature       Date:  2007-11-14       Impact factor: 49.962

7.  Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A.

Authors:  J M M Howson; N M Walker; D Clayton; J A Todd
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

8.  Interaction between Treg apoptosis pathways, Treg function and HLA risk evolves during type 1 diabetes pathogenesis.

Authors:  Sanja Glisic; Parthav Jailwala
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.